NMDAR Antagonist (GM-2505/Bretisilocin)
Major Depressive Disorder
Phase 2Acquired by AbbVie (2024)
Key Facts
Indication
Major Depressive Disorder
Phase
Phase 2
Status
Acquired by AbbVie (2024)
Company
About Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a private, clinical-stage biotech leveraging a proprietary AI-powered discovery platform to develop next-generation, non-hallucinogenic neuroplastogens and other novel compounds for major depressive disorder, anxiety, and opioid use disorder. The company has advanced multiple candidates into Phase 2 trials, secured a significant collaboration with AbbVie, and is backed by notable investors like Y Combinator and Prime Movers Lab. With a seasoned leadership team from top biopharma and academia, Gilgamesh is positioned at the forefront of the emerging precision psychiatry sector, aiming to address the global mental health crisis with safer, more effective therapies.
View full company profileOther Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| CLE-100 | Clexio Biosciences | Phase 2 |
| Proliv™Rx | Neurolief | Phase 2 |